Ignite Creation Date:
2024-05-05 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00263744
Status:
COMPLETED
Last Update Posted:
2009-01-08
First Post:
2005-12-08
Brief Title:
Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive
Sponsor:
MedImmune LLC
Organization:
MedImmune LLC
Study Overview
Official Title:
A Phase III Study to Evaluate the Safety and Immunogenicity of MEDI-517 a Virus-Like Particle Vaccine Against Human Papillomavirus HPV Types 16 and 18 in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive
Status:
COMPLETED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to describe the safety of 40 mg MEDI-517 with a control of aluminum hydroxide when given to healthy adult women who have evidence of HPV-16 andor HPV-18 DNA detected in cervical brushings
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None